Promoting Cognitive Health in Schizophrenia (iCogCA)
Schizophrenia, Cognition
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring intervention, cognitive remediation, metacognition, psychosis
Eligibility Criteria
Inclusion Criteria: Diagnosis of affective or non-affective psychosis or related disorder; Follow-up and treatment by a clinician at one of the services mentioned above; Participants symptomatically stable and capable of using the online platforms and participating in intervention groups, as judged by their primary clinicians (i.e., psychiatrist, case manager); Participants must have access to a private space (i.e., a room where the participant can be alone) to ensure confidentiality for the group; Participants must be able to nominate an emergency contact and to agree to allow researchers to contact their clinician and/or emergency services in the event of an emergency during study procedures. Exclusion Criteria: Intellectual disability; Hospitalization at the time of recruitment; Inability to speak or read English or French; High suicide risk as per evaluation.
Sites / Locations
- Faculty of Medicine, University of British Columbia
- Kingston Health Sciences Centre, Queen's University
- Institute of Mental Health Research, University of Ottawa
- Ontario Shoares Centre for Mental Health Sciences, University of Toronto
- Douglas Mental Health University Institute
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Cognitive remediation
MetaCognitive Training
CR was developed by Dr. Bowie (PI). Approximately 60% of CR sessions are spent on cognitive training activities, 20% on developing, monitoring, and flexibly adjusting problem-solving strategies, and 20% on transfer activities. Transfer includes discussing and role-playing how cognitive skills and strategies are applied in everyday life and teaches potential compensatory strategies for overcoming cognitive challenges. Targeted cognitive domains are processing speed, attention, memory, and executive functions, which are all commonly impaired in psychosis. The manual includes 1.5-hour sessions and uses Brain Training Pro and will be offered over an 8-week period. Zoom Health will be used for group transfer activities.
MCT, developed by Drs. Moritz (co-applicant) and Woodward (PI), is based in the theoretical foundations of CBT, but targets the biases underlying symptoms rather than symptoms directly. MCT includes eight modules targeting common cognitive errors and reasoning biases in schizophrenia that have, through decades of research, been shown to contribute to delusions (e.g., jumping to conclusions). MCT will be offered to groups of up to 8 participants over 12 sessions of 45-60 min each (two per week) through Zoom Health. Session aims include raising participants' awareness of distortions and prompting them to critically reflect on, expand upon, and change their current repertoire of problem-solving strategies.